TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Oncology
Recent trends in molecular testing and maintenance targeted therapies in ovarian cancer
Key Statistics
- 70% — Advanced-stage relapse after 1ST-line chemo
- ~50% — HGSC with HRD (TCGA)
- 20% — HGSC with BRCA1/2mut (TCGA)
Don't-miss facts
-
70% advanced ovarian cancer relapse rate after first-line chemo response is the rationale for maintenance therapy
-
PARPi mechanism = PARP trapping + synthetic lethality; BRCA1/2mut/HRD tumours respond best
-
Three approved PARPi: olaparib, niraparib, rucaparib. Olaparib first-line up to 2 yrs (+bevacizumab 15 mo); niraparib up to 3 yrs
-
MyChoice® HRD-positive GIS cut-off = 42 (PAOLA-1/PRIMA); VELIA used 33
-
PAOLA-1: olaparib+bevacizumab gives no benefit if HRD-negative (HR 1.0) – NICE/FDA/EMA restrict combo to HRD+/BRCA1/2mut
-
SOLO-1 5-yr PFS: 56 vs 13.8 months (olaparib vs placebo, BRCA1/2mut, HR 0.33)
-
PARPi ↑ severe AEs (RR 2.62) & MDS/AML risk (OR 2.63) – balance against PFS gain using QA-PFS/Q-TWIST
-
Mandatory consent for germline BRCA1/2 blood testing; tissue testing consent is good practice but not obligatory
HRD testing routes
BRCA1/2 mutation (germline/tumour) Non-BRCA HRR gene mutation (~30%)
Epigenomic silencing (BRCA1/RAD51C methylation) Genomic scar (GIS – MyChoice®/FoundationFocus®)
Mutational signature (SBS3) Functional (RAD51) – not clinic-ready
Abbreviation Key
- HGSC — high-grade serous carcinoma
- LOH/LST/TAI — loss of heterozygosity / large-scale transitions / telomeric allelic imbalance
- HRD — homologous recombination deficiency
- SBS — single-base substitution (mutational signature)
- HRR — homologous recombination repair
- PFS/OS — progression-free/overall survival
- PARP/PARPi — poly-ADP-ribose polymerase / PARP inhibitor
- HR — hazard ratio
- BRCA1/2mut — BRCA1/2 mutation
- PSROC — platinum-sensitive relapsed ovarian cancer
- gBRCA/sBRCA/tBRCA — germline/somatic/tumour BRCA mutation
- NMRD — no macroscopic residual disease
- TCGA — The Cancer Genome Atlas
- NICE — National Institute for Health and Care Excellence
- DDR — DNA damage response
- CDF — Cancer Drugs Fund
- SSB/DSB — single-/double-strand DNA break
- EMA/FDA — European Medicines Agency / US Food and Drug
- NHEJ — nonhomologous end-joining Administration
- BER/NER/MMR — base excision/nucleotide excision/mismatch
- GLH — Genomic Laboratory Hub repair
- STIC — serous tubal intraepithelial carcinoma
- GIS — genomic instability score
- QoL/QA-PFS/Q-TWIST — quality of life / quality-adjusted
- PFS / MDS/AML — myelodysplastic syndrome / acute myeloid leukaemia quality-adjusted time without symptoms of toxicity
Source: Darwish A et al. Recent trends in molecular testing and maintenance targeted therapies in ovarian cancer. The Obstetrician & Gynaecologist 2023;25:220–228. doi:10.1111/tog.12880
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).